Health and Healthcare
MannKind Raises Over $50 Million (MNKD, PFE)
Published:
Last Updated:
MannKind Corporation (NASDAQ: MNKD) is getting hit after the company announced that it priced a secondary offering of 7,400,000 shares of its common stock. While the press release does not say what price the deal came at, the syndicate group told us this went out at $7.35 per share. The company’s chairman, CEO, and principal stockholder, Alfred E. Mann, is purchasing 1,000,000 of these shares from the underwriters.
This figure comes to north of $54 million before deducting fees. All shares are being sold by the company itself, so all proceeds from the offering will head into the MannKind coffers. Jefferies is listed as the sole book-running manager, and the co-manager is listed as Rodman & Renshaw. The underwriters a 30-day over-allotment option to purchase up to an additional 960,000 shares.
It was just in June that the company closed upon the purchase of the insulin assets and facility from Pfizer, Inc. (NYSE: PFE). That was listed as only a $3 million transaction.
MannKind shares are down 9.5% at $7.36 as of 9:50 on almost 1.35 million shares. Its 52-week trading range is $2.00 to $9.25.
JON C. OGG
AUGUST 5, 2009
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.